Brokerages Set Trevi Therapeutics, Inc. (NASDAQ:TRVI) Target Price at $15.94

Trevi Therapeutics, Inc. (NASDAQ:TRVI) has earned an average rating of “Buy” from the ten analysts that are currently covering the firm, Marketbeat.com reports. Seven equities research analysts have rated the stock with a buy recommendation and three have issued a strong buy recommendation on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $17.56.

TRVI has been the topic of several recent research reports. Raymond James raised Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and upped their price objective for the stock from $9.00 to $29.00 in a report on Monday, March 10th. B. Riley reaffirmed a “buy” rating and set a $20.00 price objective (up from $11.00) on shares of Trevi Therapeutics in a report on Wednesday. Oppenheimer increased their price target on Trevi Therapeutics from $12.00 to $20.00 and gave the company an “outperform” rating in a report on Tuesday, March 11th. D. Boral Capital restated a “buy” rating and set a $21.00 price target on shares of Trevi Therapeutics in a report on Wednesday. Finally, HC Wainwright restated a “buy” rating and set a $12.50 price target on shares of Trevi Therapeutics in a report on Wednesday.

Insider Buying and Selling at Trevi Therapeutics

In other Trevi Therapeutics news, insider Farrell Simon sold 81,313 shares of the company’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $6.75, for a total value of $548,862.75. Following the transaction, the insider now owns 76,900 shares of the company’s stock, valued at $519,075. This represents a 51.39 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 24.37% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Trevi Therapeutics

Hedge funds have recently bought and sold shares of the business. Summit Investment Advisors Inc. grew its position in Trevi Therapeutics by 84.2% in the 4th quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company’s stock valued at $26,000 after acquiring an additional 2,894 shares during the last quarter. BNP Paribas Financial Markets grew its position in shares of Trevi Therapeutics by 130.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock worth $40,000 after buying an additional 6,764 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of Trevi Therapeutics during the 4th quarter worth $49,000. Squarepoint Ops LLC bought a new position in shares of Trevi Therapeutics during the 4th quarter worth $58,000. Finally, Two Sigma Advisers LP bought a new position in shares of Trevi Therapeutics during the 4th quarter worth $66,000. Institutional investors own 95.76% of the company’s stock.

Trevi Therapeutics Price Performance

Shares of TRVI opened at $6.47 on Tuesday. The stock has a market capitalization of $497.32 million, a price-to-earnings ratio of -14.70 and a beta of 0.90. Trevi Therapeutics has a 1 year low of $2.30 and a 1 year high of $7.39. The business’s 50 day simple moving average is $4.60 and its 200-day simple moving average is $3.75.

Trevi Therapeutics (NASDAQ:TRVI) last issued its quarterly earnings data on Tuesday, March 18th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.01. On average, sell-side analysts expect that Trevi Therapeutics will post -0.49 earnings per share for the current year.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.